AN2 Therapeutics
pipeline targets high unmet needs in rare chronic and serious infectious diseases boron chemistry approach enables targeting of novel biological targets lung disease an therapeutics | AN2 Therapeutics
Company
Deck Type
Sector
Industry
Deck date
August 2022
Slide
6 of 25
Similar slides by AN2 Therapeutics
See diffirences between slides (animation)
IPO
March 2022
pipeline targets high unmet needs in rare chronic and serious infectious diseases lung disease boron chemistry approach enables targeting of novel biological targets mid phase topline data japan attest as an therapeutics | AN2 Therapeutics
Related slides by other companies
Matinas BioPharma
Investor Presentation
February 2024
high unmet medical need in treatment of invasive aspergillosis | Matinas BioPharma
Matinas BioPharma
Investor Presentation
January 2024
high unmet medical need in treatment of invasive aspergillosis | Matinas BioPharma
Ocuphire Pharma
Results
October 2022
preferred practice pattern reveals high unmet need in mild moderate and severe patients normal or minimal no no no no no sometimes rarely an oral option treatment options across all stages no no usually | Ocuphire Pharma
AstraZeneca
Investor Presentation
March 2022
investing in rare disease | AstraZeneca
Other recent decks by AN2 Therapeutics
See all presentations (2 decks)
IPO
March 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io